ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gout and uric acid"

  • Abstract Number: 121 • 2015 ACR/ARHP Annual Meeting

    Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting

    Aki Shiozawa1, Erin Buysman2, Stephanie Korrer2 and Hyon Choi3, 1Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 2Health Economics and Outcomes Research, Optum, Eden Prairie, MN, 3Massachussetts General Hospital/Harvard Medical School, Boston, MA

    Background/Purpose: Gout is a common chronic inflammatory condition due to hyperuricemia. Gout patients typically have the clinical manifestation of acute painful flare attacks. While the…
  • Abstract Number: 218 • 2015 ACR/ARHP Annual Meeting

    Diet-Wide Association Study of Serum Urate Levels in 13,782 Individuals of European Ancestry

    Tony R. Merriman1, Nicola Dalbeth2, Ruth Topless3 and Tanya Flynn3, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Otago, Dunedin, New Zealand

    Background/Purpose: Gout is a consequence of an innate immune reaction to monosodium urate crystals deposited in joints. Acute gout attacks are commonly triggered by dietary…
  • Abstract Number: 219 • 2015 ACR/ARHP Annual Meeting

    Targeted Deep Resequencing Identifies MRP4/ABCC4 as a Gout Risk Locus in the New Zealand Mä�ori and Pacific Island Populations

    Tony R. Merriman1, James Boocock2, Callum Tanner2, Murray Cadzow2, Amanda Phipps-Green2, Lisa K. Stamp3, Nicola Dalbeth4, Jennie Harre Hindmarsh5, David B. Mount6, Hyon Choi7 and Eli A. Stahl8, 1Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 4Department of Medicine, University of Auckland, Auckland, New Zealand, 5Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 6Renal Division, Brigham and Women's Hospital, Boston, MA, 7Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Genetic variants in uric acid transporters that control serum urate levels in Europeans have been identified by genome-wide association studies. However there is no…
  • Abstract Number: 228 • 2015 ACR/ARHP Annual Meeting

    Gout and Risk of Non-Vertebral Osteoporotic Fracture

    Seoyoung C. Kim1, Julie M. Paik2, Jun Liu3, Gary C. Curhan2 and Daniel H. Solomon4, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Renal Division, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Prior studies suggest an association between osteoporosis, systemic inflammation and pro-inflammatory cytokines such as IL-1 and IL-6. Gout is a common inflammatory arthritis characterized…
  • Abstract Number: 229 • 2015 ACR/ARHP Annual Meeting

    Uric Acid and Incident Dementia over 10 Years

    Pascal Richette1, Aicha Soumare2, Stéphanie Debette2, Thomas Bardin3,4 and Christophe Tzourio2, 1Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, 2INSERM Research Center for Epidemiology and Biostatistics (U897) Team Neuroepidemiology, Bordeaux, France, 3Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 4Rhumatology Departement, Hôpital Lariboisière, Paris, France

    Background/Purpose: In patients with gout, maintaining the serum uric acid (SUA) levels too low with ULT is a matter of concern because UA is thought…
  • Abstract Number: 242 • 2015 ACR/ARHP Annual Meeting

    Higher Serum Uric Acid Levels Are Associated with an Increased Risk of Flares: A Systematic Review

    Aki Shiozawa1, Shelagh M Szabo2, Antoinette Cheung2, Anna Bolzani2 and Hyon K. Choi3, 1Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 2Redwood Outcomes, Vancouver, BC, Canada, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Acutely painful flares represent the typical clinical burden of gout. Effective therapy can reduce serum uric acid (sUA) levels; however, epidemiologic evidence for the…
  • Abstract Number: 245 • 2015 ACR/ARHP Annual Meeting

    Seasonal Variation in Acute Gouty Arthritis: Data from Nationwide Inpatient Sample

    Paras Karmacharya1, Ranjan Pathak2, Madan Aryal2, Smith Giri3 and Anthony Donato4, 1Internal Medicine, Reading Health System, WEST READING, PA, 2Internal medicine, Reading Health System, West Reading, PA, 3Internal medicine, University of Tennessee Health Science Center, Memphis, TN, 4Internal, Reading Health System, Salt Lake, UT

    Background/Purpose: Studies describing seasonal variations in acute gouty arthritis note a seasonal trend, but disagree on timing, with most showing a peak in spring months…
  • Abstract Number: 935 • 2015 ACR/ARHP Annual Meeting

    Microrna-146a Provides Feedback Regulation of Monosodium Urate-Induced Gouty Arthritis in Mice By Targeting Tumor Necrosis Factor Receptor Associated Factor 6 and Interleukin-1 Receptor-Associated Kinase 1

    Quan-Bo Zhang1,2, Jing-Guo Zhou3, Cong-Cong Yin1, Yu-Feng Qing4, Chang-Gui Li5, Li Zhou1 and Qing-Sheng Mi6, 1Immunology Program, Department of Dermatology, Henry Ford Health System, Detroit, MI, 2Geriatrics, Affliated hospital of North Sichuan Medical College, Nanchong, China, 3Department of Rheumatology and Immunology, Affliated hospital of North Sichuan Medical College, Nanchong, China, 4Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nanchong, China, 5Affiliated Hospital of Qingdao University, Qingdao, China, 6Immunology, Dermatology, Henry Ford Health System, Detroit, MI

    Background/Purpose: MicroRNAs (miRNAs) have been shown to serve as important regulators for inflammatory and immune responses and are implicated in several immune disorders including gouty…
  • Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting

    Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)

    Na Lu1, Sharan K. Rai2, Jeewoong Choi3 and Hyon K. Choi1, 1Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA

    Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
  • Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting

    A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

    Alexandra Steinberg1, Harinder Chera1, Yun-Jung Choi1, Robert Martin1, Charles McWherter1, Yunbin Zhang2, Pol Boudes1 and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, 1Cymabay Therapeutics, Newark, CA, 2INC Research, Raleigh, NC

    Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout.  It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
  • Abstract Number: 2355 • 2015 ACR/ARHP Annual Meeting

    Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial

    Na Lu1, Yuqing Zhang2, Sharan K. Rai3, Gary C. Curhan4 and Hyon K. Choi5, 1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2BUSM, Boston, MA, 3Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 4Renal Division, Brigham and Women's Hospital, Boston, MA, 5Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% of cases in the US), underscoring…
  • Abstract Number: 91 • 2015 ACR/ARHP Annual Meeting

    Coevolution of a Uric Acid Transporter and Uricase: Implications for Gout

    Philip K. Tan1, Eric A. Gaucher2 and Jeffrey N. Miner3, 1Ardea Biosciences, San Diego, CA, 2Georgia Institute of Technology, Atlanta, GA, 3Discovery Biology, Ardea Biosciences, San Diego, CA

    Background/Purpose: Gout is caused by chronic hyperuricemia, leading to uric acid deposition. Humans and apes have relatively high serum uric acid (sUA) levels due to…
  • Abstract Number: 2958 • 2014 ACR/ARHP Annual Meeting

    Polygenic Analysis of Transport, Metabolism and Immune Related Genomic Compartments in Serum Urate and Gout

    Eli A. Stahl1, Tony R. Merriman2, Amanda Dobbyn3, David B. Mount4, Peter Kraft5 and Hyon K. Choi6, 1Mt Sinai School of Medicine, New York City, NY, 2Department of Biochemistry, University of Otago, Dunedin, New Zealand, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Renal Division, Brigham and Women's Hospital, Boston, MA, 5Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 6Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Genome wide association studies (GWAS) have identified loci associated with complex traits, and the current challenge is to glean biological insights from these findings.…
  • Abstract Number: 2959 • 2014 ACR/ARHP Annual Meeting

    Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout

    Tony R. Merriman1, Marilyn E. Merriman1, Ruth Topless1, Sara Altaf2, Grant Montgomery3, Christopher Franklin4, Gregory T. Jones5, Andre M. van Rij2, Douglas HN White6, Lisa K. Stamp7, Nicola Dalbeth8 and Amanda Phipps-Green1, 1Department of Biochemistry, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Queensland Institute of Medical Research, Brisbane, Australia, 4University of Auckland, Auckland, New Zealand, 5Surgery, University of Otago, Dunedin, New Zealand, 6Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7University of Otago, Christchurch, New Zealand, 8Department of Medicine, University of Auckland, Auckland, New Zealand

    Background/Purpose: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Ten are established, with a further 18 of weaker effect more recently detected.…
  • Abstract Number: 2961 • 2014 ACR/ARHP Annual Meeting

    Conditional Analysis of 30 Serum Urate Loci Identifies 25 Additional Independent Effects

    Eli Stahl1, Hyon K. Choi2, Murray Cadzow3, Tanya Flynn3, Ruth Topless4 and Tony R. Merriman4, 1Mt Sinai School of Medicine, New York City, NY, 2Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3University of Otago, Dunedin, New Zealand, 4Department of Biochemistry, University of Otago, Dunedin, New Zealand

    Background/Purpose: Single variants in 30 genetic loci have been associated with serum urate levels in Europeans by meta-analysis of summary statistics of 48 individual genome-wide…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology